Apyx Medical Inc (APYX) Peer Comparison

$2.96

$-0.09 (-2.95%)

As on 27-Aug-2026 12:33EDT

Market cap

$131 Mln

Revenue (TTM)

$58 Mln

P/E Ratio

--

P/B Ratio

12

Div. Yield

0 %

Edit

	Apyx Medical Inc (APYX)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Market cap ($ Mln)	131	12,753	10,906	9,762	10,222
Revenue ($ Mln)	58	1,505	613	2,589	785
Net Profit ($ Mln)	-8.63	160.59	-188.05	222.40	41.54
Net Margin (%)	-14.78	10.67	-30.68	8.59	5.29
RoE (%)	-70.29	10.86	-28.10	3.04	1.97
Price to Earnings	--	79.35	--	44.47	251.57
Price-To-Book	11.97	8.41	16.38	1.26	4.84

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Apyx Medical Inc (APYX)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Operating Revenue	58.42	1,504.87	612.84	2,589.30	785.10
Cost of Revenue	38.59	483.98	127.96	1,245.50	384.30
Gross Profit	19.03	942.44	393.22	1,343.60	347.62
Operating Expenses	23.37	833.56	565.37	1,108.90	335.50
Operating Profit (EBIT)	-3.54	187.34	-80.49	235.00	65.30
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-7.97	203.83	-192.83	350.40	52.15
Provision for Tax	0.44	43.24	-4.79	128.00	10.61
Profit after Tax (Net Income)	-8.63	160.59	-188.05	222.40	41.54
Minority Interest	-0.22	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	93.19	0.00	0.00	0.00

Liabilities ($ Mln)

	Apyx Medical Inc (APYX)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Shareholder's Funds	10.66	1,530.77	682.49	7,173.90	2,112.03
Minority Interest	-0.22	0.00	0.00	0.00	0.00
Non-Current Liabilities	40.63	210.18	135.71	2,116.80	705.49
Current Liabilities	9.35	233.78	102.33	961.30	132.66
Total Liabilities	66.84	1,826.52	893.49	10,576.50	2,949.70

Assets ($ Mln)

	Apyx Medical Inc (APYX)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Non-Current Assets	7.92	630.60	404.74	7,231.50	1,749.63
Current Assets	53.16	1,344.12	515.78	3,020.50	1,200.55
Total Assets	66.84	1,826.52	893.49	10,576.50	2,949.70
Total Debt*	39.63	212.71	102.84	1,203.70	690.94
Net Current Assets	43.80	1,110.35	413.45	2,059.20	1,067.90

Cashflow ($ Mln)

	Apyx Medical Inc (APYX)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Cash From Operating Activities	-8.00	238.66	-46.34	532.20	117.42
Cash Flow from Investing Activities	-1.11	-404.59	-77.61	-189.70	-298.47
Cash from Financing Activities	9.58	26.53	11.89	-283.20	-15.21
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Apyx Medical Inc (APYX)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
ROCE (%)	-20.98	11.76	-22.53	8.98	1.79
ROE (%)	-70.29	10.86	-28.10	3.04	1.97
ROA (%)	-12.41	7.95	-18.00	2.02	1.36
EBIT Margin (%)	-4.09	13.63	-30.58	-5.99	9.87
Net Margin (%)	-14.78	10.67	-30.68	8.59	5.29
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Apyx Medical Inc (APYX)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Revenue Growth (%)	25.59	17.55	41.55	1.37	16.49
EBIT Growth (%)	78.67	17.49	-116.42	-131.06	920.91
Net Profit Growth (%)	49.97	8.72	-102.66	-30.32	400.42
EPS Growth (%)	55.74	8.12	-96.88	-29.66	394.30
Book Value Growth (%)	42.01	17.33	-12.65	2.19	2.16

Valuation Ratios

	Apyx Medical Inc (APYX)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Price / Earnings	-13.16	68.93	-34.59	--	189.42
Price / Book Value	10.15	8.58	9.90	--	4.40
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	-33.80	53.25	-43.50	--	55.90
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Apyx Medical Inc (APYX)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Debt to Equity	3.31	0.00	0.00	0.11	0.26
Short term debt to equity ratio	0.04	0.01	0.00	0.06	0.01
Current Ratio	5.68	5.75	5.04	3.14	9.05
Quick Ratio	4.53	3.86	4.46	2.33	7.64
Interest Coverage	-0.43	157.91	-38.31	8.18	3.36

Operating Efficiency Ratios

	Apyx Medical Inc (APYX)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Debtors to sales (%)	23.31	12.65	22.67	17.06	20.09
Asset Turnover	0.84	0.74	0.59	0.24	0.26
Receivable days	111.47	46.54	60.95	65.39	72.41
Inventory Days	87.32	331.92	193.84	221.09	146.53
Payable days	30.64	26.16	60.19	37.02	29.05
Cash Conversion Cycle	168.15	352.30	194.60	249.46	189.88

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly